CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 11 enrolled
Drug / intervention
Daratumumab SC +3 moredrug
Likely dose
Daratumumab SC 1800mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04302324
NCT04302324Phase 2Active
CompareCT.gov

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University·interventional·Posted Mar 10, 2020·Updated May 20, 2026

In Brief

A Phase 2 clinical trial evaluating Daratumumab SC, Clarithromycin, and 2 other interventions for Multiple Myeloma and 2 related conditions. Active but no longer recruiting, targeting 11 participants across 1 site.

Detailed Summary

This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity. This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of clarithromycin/pomalidomide/dexamethasone with daratumumab SC (D-ClaPd) will yield higher Very Good Partial Response (VGPR) rates in relapsed/refractory multiple myeloma patients than historical pomalidomide/dexamethasone treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
CountriesUnited States
CollaboratorsJanssen Scientific Affairs, LLC

Timeline

Phase 2Active
202020212022202320242025202620272028
First PostedMar 10, 2020
Enrollment StartOct 28, 2021
Primary CompletionMay 31, 2024
Study CompletionDec 28, 2027
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.3 years ago

Interventions

Daratumumab SCdrug

Given as 1800mg via injection

Clarithromycindrug

Given as 500mg oral capsule

Pomalidomidedrug

Given as 4mg oral capsule

Dexamethasonedrug

Given as 20mg IV and 20mg or 40mg oral tablets